financetom
Business
financetom
/
Business
/
WeRide (WRD) Stock Gains 5% Amid Expansion with Uber
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
WeRide (WRD) Stock Gains 5% Amid Expansion with Uber
May 26, 2025 2:06 AM

WeRide Inc ( WRD ) shares surged 5.0% to $7.21 during Tuesday's trading session after the autonomous driving company announced a global expansion of its partnership with Uber Technologies Inc ( UBER ) .

What To Know: The two firms revealed plans to roll out autonomous ride services in 15 new cities worldwide over the next five years, including several in Europe. This builds on their initial collaboration in Abu Dhabi, with Dubai soon to follow.

Under the expanded partnership, WeRide's ( WRD ) Robotaxi services will be integrated into the Uber ( UBER ) app, while Uber ( UBER ) will manage fleet operations. Notably, the rollout excludes the U.S. and China, focusing instead on untapped international markets.

Executives from both companies emphasized their shared commitment to accelerating the global adoption of autonomous mobility.

WeRide ( WRD ) CEO Tony Han highlighted the move as a key step in making autonomous technology more accessible, while Uber ( UBER ) CEO Dara Khosrowshahi called it "one of the biggest partnerships of its kind."

Read Also: Genius Sports Shares Slide After Q1 Sales Miss: What’s Going On?

How To Buy WRD Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in WeRide’s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, WRD has a 52-week high of $44.00 and a 52-week low of $6.03.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blue Owl Capital Prices $250 Million Debt Offering
Blue Owl Capital Prices $250 Million Debt Offering
May 30, 2024
05:45 PM EDT, 05/30/2024 (MT Newswires) -- Blue Owl Capital (OWL) said late Thursday it priced a $250 million offering of 6.25% senior notes due 2034 by indirect subsidiary Blue Owl Finance at 100.355%, plus applicable interest. The company plans to use the net proceeds for general corporate purposes. Price: 19.25, Change: -0.10, Percent Change: -0.52 ...
Hertz exploring options to raise financing, Bloomberg News reports
Hertz exploring options to raise financing, Bloomberg News reports
May 30, 2024
(Reuters) - Hertz Global ( HTZ ) is exploring options to raise financing, weeks after its new CEO pledged to get the company back on track following a failed bet on electric vehicles, Bloomberg News reported, citing people with knowledge of the matter. Shares of the car rental company were up 4.1% after the bell. They had hit a record...
Affinity Bancshares Agrees to Sell Affinity Bank to Atlanta Postal Credit Union
Affinity Bancshares Agrees to Sell Affinity Bank to Atlanta Postal Credit Union
May 30, 2024
05:42 PM EDT, 05/30/2024 (MT Newswires) -- Affinity Bancshares ( AFBI ) entered and agreement under which Atlanta Postal Credit Union will acquire its subsidiary Affinity Bank, the companies said Thursday. Atlanta Postal will buy substantially all assets of Affinity Bank and assume all of its liabilities in an all-cash transaction, according to the joint statement. Atlanta Postal and its...
Gilead's Trodelvy fails to meet main goal in late-stage cancer study
Gilead's Trodelvy fails to meet main goal in late-stage cancer study
May 30, 2024
May 30 (Reuters) - Gilead Sciences ( GILD ) said on Thursday its drug Trodelvy, tested in patients with bladder cancer who previously received chemotherapy and other anti-cancer therapies, did not meet the main goal of a late-stage study. The company said the drug did not meet the main goal of overall survival. In the overall study population, there was...
Copyright 2023-2026 - www.financetom.com All Rights Reserved